Oppenheimer emphasized the advancements in CRISPR’s in vivo initiatives, highlighting the comprehensive findings from the Phase 1 study of CTX310 that were presented at the American Heart Association ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback